Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

Feb 06, 2013, 13:19 ET from Reportlinker

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

http://www.reportlinker.com/p0887610/Bone-Metabolism-Therapeutics-Market-to-2018---Hyperparathyroidism-Sector-to-Decline-in-the-Absence-of-New-Product-Launches-and-Increased-Generic-Erosion-for-Zemplar-Hectorol-and-Sensipar.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

 

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

 

Summary

 

GBI Research, the leading business intelligence provider, has released its latest research, "Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar", which provides insights into bone metabolic disease therapeutics until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases. The report also provides the share of generics in global bone metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each of the four indications. The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. The report also includes insights into the bone metabolic diseases R&D product pipeline and explores the competitive landscape, including major players in the bone metabolism therapeutics market. Finally, the report also includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market.

 

GBI Research's analysis shows that the overall global bone metabolism therapeutics market for the four indications (which includes osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases) was valued at $15 billion in 2010, growing from $10.1 billion in 2002 and indicating a CAGR of 5.2%. GBI Research forecasts the market to grow at a CAGR of 7.7% between 2010 and 2018 to record a sales value of $27.1 billion by 2018. The growth in the bone metabolism therapeutics market is mainly due to the contribution of osteoporosis market. The revenue of osteoporosis market alone has approximately 68% of the total bone metabolism revenue. So, the global bone metabolism market is growing inspite of the declining market nature of the rest of therapeutics areas discussed here.

 

Scope

 

- Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2018 for the three indications – osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Share of the generics in the global bone metabolism therapeutics market and for the market of each indication that is covered in the report.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global bone metabolism therapeutics market, including top companies benchmarking. The key companies studied in this report are Amgen Inc., Abbott Laboratories, Genzyme Corporation, Merck & Co. Inc. and Novartis AG.

- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorders therapeutics market.

 

Reasons to buy

 

- Align your product portfolio to the markets with high growth potential.

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

 

 

 

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 9

2 Introduction 11

3 Bone Metabolism Therapeutics Market to 2018 - Market Overview 12

3.1 Introduction 12

3.1.1 Revenue 12

3.1.2 Annual Cost of Treatment 13

3.1.3 Treatment Usage Patterns 14

4 Bone Metabolism Therapeutics Market to 2018 - Geographical Landscape 16

4.1 Revenue Analysis by Geography 16

4.2 The US 18

4.2.1 Revenue 18

4.2.2 Annual Cost of Treatment 19

4.2.3 Treatment Usage Patterns 20

4.3 Top Five Countries of Europe 22

4.3.1 Revenue 22

4.3.2 Annual Cost of Treatment 24

4.3.3 Treatment Usage Patterns 25

4.4 Japan 27

4.4.1 Revenue 27

4.4.2 Annual Cost of Treatment 28

4.4.3 Treatment Usage Patterns 29

5 Bone Metabolism Therapeutics Market to 2018 - Therapeutic Landscape 31

5.1 Osteoporosis Therapeutics Market 31

5.1.1 Introduction 31

5.1.2 Revenue 31

5.1.3 Annual Cost of Treatment 35

5.1.4 Treatment Usage Patterns 36

5.1.5 Treatment Flow Algorithm 38

5.1.6 Drivers and Barriers for the Osteoporosis Therapeutics Market 39

5.2 Paget's Disease of Bone Therapeutics Market 40

5.2.1 Introduction 40

5.2.2 Revenue 40

5.2.3 Annual Cost of Treatment 45

5.2.4 Treatment Usage Patterns 46

5.2.5 Treatment Flow Algorithm 48

5.2.6 Drivers and Barriers for the Paget's Disease of Bone Therapeutics Market 49

5.3 Hyperparathyroidism Therapeutics Market 50

5.3.1 Introduction 50

5.3.2 Revenue 50

5.3.3 Annual Cost of Treatment 55

5.3.4 Treatment Usage Patterns 56

5.3.5 Treatment Flow Algorithm 58

5.3.6 Drivers and Barriers for the Hyperparathyroidism Therapeutics Market 59

5.4 Bone Metastases Therapeutics Market 60

5.4.1 Introduction 60

5.4.2 Revenue 60

5.4.3 Annual Cost of Treatment 65

5.4.4 Treatment Usage Patterns 66

5.4.5 Treatment Flow Algorithm 68

5.4.6 Drivers and Barriers for the Bone Metastases Therapeutics Market 68

6 Bone Metabolism Therapeutics Market to 2018 - Pipeline Analysis 70

6.1 Introduction 70

6.2 Bone Metabolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 72

6.2.1 Filed Molecules 72

6.2.2 Phase III 73

6.2.3 Phase II 78

6.2.4 Phase I 80

6.2.5 Preclinical Phase 81

6.2.6 Discovery Phase 82

6.3 Profiles of Promising Molecules in the Bone Metabolism Therapeutics Market 82

6.3.1 Alpharadin (radium-223 chloride) 82

6.3.2 Orazol (Zoledronic acid) 83

6.3.3 Xgeva (denosumab) 83

6.3.4 Boniva (ibandronate sodium hydrate) 84

6.3.5 Odanacatib (odanacatib) 85

6.3.6 GTH-42V 85

6.3.7 Viviant (bazedoxifene) 86

7 Bone Metabolism Therapeutics Market to 2018 - Competitive Profiling 87

7.1 Competitive Profiling 87

7.1.1 Amgen Inc. 87

7.1.2 Abbott Laboratories 89

7.1.3 Genzyme Corporation 90

7.1.4 Merck & Co., Inc. 91

7.1.5 Novartis AG 93

8 Bone Metabolism Therapeutics Market to 2018 - Strategic Consolidations 95

8.1 Mergers and Acquisitions 95

8.1.1 Segmentation by Deal Value 97

8.1.2 Segmentation by Geography 99

8.2 Co-development Deals 100

8.2.1 Summary of Co-development Deals 101

8.3 Licensing Deals 102

8.3.1 Summary of Licensing Deals 103

9 Bone Metabolism Therapeutics Market to 2018 - Appendix 105

9.1 Market Definitions 105

9.2 Abbreviations 105

9.3 Sources 106

9.4 Research Methodology 106

9.4.1 Coverage 106

9.4.2 Secondary Research 107

9.4.3 Primary Research 107

9.5 Therapeutic Landscape 108

9.5.1 Epidemiology-based Forecasting 108

9.5.2 Market Size by Geography 110

9.6 Geographical Landscape 111

9.7 Pipeline Analysis 111

9.8 Competitive Landscape 111

9.8.1 Expert Panel Validation 111

9.9 Contact Us 111

9.10 Disclaimer 112

 

 

 

List of Tables

 

Table 1: Bone Metabolism Therapeutics Market, Global, Revenue ($bn), 2002-2010 12

Table 2: Bone Metabolism Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 12

Table 3: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 13

Table 4: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 13

Table 5: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 14

Table 6: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 15

Table 7: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 17

Table 8: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 17

Table 9: Bone Metabolism Therapeutics Market, The US, Revenue ($bn), 2002-2010 18

Table 10: Bone Metabolism Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 18

Table 11: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 19

Table 12: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2018 19

Table 13: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2010 20

Table 14: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 21

Table 15: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 22

Table 16: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2018 22

Table 17: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue ($bn), 2002-2010 23

Table 18: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue Forecasts ($bn), 2010-2018 23

Table 19: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 24

Table 20: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2018 24

Table 21: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2010 25

Table 22: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2018 26

Table 23: Bone Metabolism Therapeutics Market, Japan, Revenue ($bn), 2002-2010 27

Table 24: Bone Metabolism Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2018 27

Table 25: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 28

Table 26: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 28

Table 27: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2010 29

Table 28: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 30

Table 29: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2002-2010 31

Table 30: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 32

Table 31: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 32

Table 32: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 33

Table 33: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 35

Table 34: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 35

Table 35: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 36

Table 36: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 37

Table 37: Paget's Disease of Bone Therapeutics Market, Global, Revenue ($m), 2002-2010 41

Table 38: Paget's Disease of Bone Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 41

Table 39: Paget's Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 42

Table 40: Paget's Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018 43

Table 41: Paget's Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 45

Table 42: Paget's Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 45

Table 43: Paget's Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 46

Table 44: Paget's Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 47

Table 45: Hyperparathyroidism Therapeutics Market, Global, Revenue ($m), 2002-2010 51

Table 46: Hyperparathyroidism Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 51

Table 47: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 52

Table 48: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018 53

Table 49: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 55

Table 50: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 55

Table 51: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 56

Table 52: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 57

Table 53: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2002-2010 61

Table 54: Bone Metastases Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 61

Table 55: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 62

Table 56: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018 63

Table 57: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 65

Table 58: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 65

Table 59: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010 66

Table 60: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2018 67

Table 61: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, NDA-filed Molecules,2011 72

Table 62: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase III Molecules,2011 73

Table 63: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase II Molecules,2011 78

Table 64: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase I Molecules,2011 80

Table 65: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase Molecules,2011 81

Table 66: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Discovery Phase Molecules,2011 82

Table 67: Bone Metabolism Therapeutics Market, Global, M&A, 2009-2011 96

Table 68: Bone Metabolism Therapeutics Market, M&A Deals, by Value ($m) 2009-2011 98

Table 69: Bone Metabolism Therapeutics Market, Co-development, by Geography, 2009-2011 100

Table 70: Bone Metabolism Therapeutics Market, Licensing Deals, by Geography, 2009-2011 102

 

 

 

List of Figures

 

Figure 1: Bone Metabolism Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2018 12

Figure 2: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 13

Figure 3: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 14

Figure 4: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2018 16

Figure 5: Bone Metabolism Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2018 18

Figure 6: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2018 19

Figure 7: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2018 20

Figure 8: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2018 22

Figure 9: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue Forecasts ($bn), 2002-2018 23

Figure 10: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2018 24

Figure 11: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2018 25

Figure 12: Bone Metabolism Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2018 27

Figure 13: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2018 28

Figure 14: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2018 29

Figure 15: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2018 31

Figure 16: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2018 32

Figure 17: Osteoporosis Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 34

Figure 18: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 35

Figure 19: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 36

Figure 20: Osteoporosis Therapeutics Market, Treatment Flow Algorithm 38

Figure 21: Osteoporosis, Market Drivers and Barriers 39

Figure 22: Paget's Disease of Bone Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 41

Figure 23: Paget's Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 42

Figure 24: Paget's Disease of Bone Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 44

Figure 25: Paget's Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 45

Figure 26: Paget's Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 46

Figure 27: Paget's Disease of Bone Therapeutics Market, Treatment Flow Algorithm 48

Figure 28: Paget's Disease of Bone, Market Drivers and Barriers 49

Figure 29: Hyperparathyroidism Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 50

Figure 30: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 52

Figure 31: Hyperparathyroidism Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 54

Figure 32: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 55

Figure 33: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 56

Figure 34: Hyperparathyroidism Therapeutics Market, Treatment Flow Algorithm 58

Figure 35: Hyperparathyroidism, Market Drivers and Barriers 59

Figure 36: Bone Metastases Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 61

Figure 37: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 62

Figure 38: Bone Metastases Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 64

Figure 39: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 65

Figure 40: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2018 66

Figure 41: Bone Metastases Therapeutics Market, Treatment Flow Algorithm 68

Figure 42: Bone Metastases, Market Drivers and Barriers 69

Figure 43: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 70

Figure 44: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 71

Figure 45: Bone Metabolism Therapeutics Market, Global, SWOT - Amgen Inc. 88

Figure 46: Bone Metabolism Therapeutics Market, Global, SWOT - Abbott Laboratories 89

Figure 47: Bone Metabolism Therapeutics Market, Global, SWOT - Genzyme Corporation 90

Figure 48: Bone Metabolism Therapeutics Market, Global, SWOT - Merck & Co., Inc. 92

Figure 49: Bone Metabolism Therapeutics Market, Global, SWOT - Novartis AG 94

Figure 50: Bone Metabolism Therapeutics Market, Global, Deals by Indication, 2009-2011 95

Figure 51: Bone Metabolism Therapeutics Market, M&A Deals, by Value ($m) 2009-2011 97

Figure 52: Bone Metabolism Therapeutics Market, M&A Deals, by Geography ($m) 2009-2011 99

Figure 53: Bone Metabolism Therapeutics Market, Licensing Deals, by Geography, 2009-2011 103

Figure 54: GBI Research Market Forecasting Model 110

 

 

 

Companies Mentioned

 

Amgen Inc.

Abbott Laboratories

Genzyme Corporation

Merck & Co., Inc.

Novartis AG

 

 

 

To order this report:

Therapy Industry: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

 

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com